Financings In Brief: ImunoGen
Executive Summary
ImmunoGen: Completes sale of $3.6 mil. of subordinated convertible debentures to a "small number of European investors," Cambridge, Mass.-based ImmunoGen reports Aug. 17. The debentures are convertible to common stock from Oct. 2 through July 31, 1996 at a predetermined conversion rate that is a discount to the market at the time of transaction. As of June 30, ImmunoGen had approximately $3 mil. in cash and equivalents on hand...